197 related articles for article (PubMed ID: 37651917)
1. Comparison of three
Dos Santos SN; Wuest M; Jans HS; Woodfield J; Nario AP; Krys D; Dufour J; Glubrecht D; Bergman C; Bernardes ES; Wuest F
Nucl Med Biol; 2023; 124-125():108383. PubMed ID: 37651917
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of a 2-nitroimidazole derivative N-(4-[
Nario AP; Woodfield J; Dos Santos SN; Bergman C; Wuest M; Araújo YB; Lapolli AL; West FG; Wuest F; Bernardes ES
EJNMMI Radiopharm Chem; 2022 Jun; 7(1):13. PubMed ID: 35697954
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Ester Hydrolysis as a New Approach in Development of Positron Emission Tomography Tracers for Imaging Hypoxia.
Zhang L; Yao X; Cao J; Hong H; Zhang A; Zhao R; Zhang Y; Zha Z; Liu Y; Qiao J; Zhu L; Kung HF
Mol Pharm; 2019 Mar; 16(3):1156-1166. PubMed ID: 30676751
[TBL] [Abstract][Full Text] [Related]
4. Positron Emission Tomography (PET) and Pharmacokinetics: Classical Blood Sampling Versus Image-Derived Analysis of [18F]FAZA and [18F]FDG in a Murine Tumor Bearing Model.
Jans HS; Yang XH; Brocks DR; Kumar P; Wuest M; Wiebe LI
J Pharm Pharm Sci; 2018; 21(1s):32s-47s. PubMed ID: 29702045
[TBL] [Abstract][Full Text] [Related]
5. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results.
Reischl G; Dorow DS; Cullinane C; Katsifis A; Roselt P; Binns D; Hicks RJ
J Pharm Pharm Sci; 2007; 10(2):203-11. PubMed ID: 17706178
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.
Piert M; Machulla HJ; Picchio M; Reischl G; Ziegler S; Kumar P; Wester HJ; Beck R; McEwan AJ; Wiebe LI; Schwaiger M
J Nucl Med; 2005 Jan; 46(1):106-13. PubMed ID: 15632040
[TBL] [Abstract][Full Text] [Related]
7.
Grkovski M; Emmas SA; Carlin SD
J Nucl Med; 2017 Oct; 58(10):1567-1573. PubMed ID: 28360207
[TBL] [Abstract][Full Text] [Related]
8. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA).
Postema EJ; McEwan AJ; Riauka TA; Kumar P; Richmond DA; Abrams DN; Wiebe LI
Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1565-73. PubMed ID: 19430784
[TBL] [Abstract][Full Text] [Related]
9. PET Imaging of L-Type Amino Acid Transporter (LAT1) and Cystine-Glutamate Antiporter (x
Krys D; Mattingly S; Glubrecht D; Wuest M; Wuest F
Mol Imaging Biol; 2020 Dec; 22(6):1562-1571. PubMed ID: 32789819
[TBL] [Abstract][Full Text] [Related]
10. Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [¹⁸F]-fluoro-azomycinarabino-furanoside ([¹⁸F]FAZA).
Maier FC; Kneilling M; Reischl G; Cay F; Bukala D; Schmid A; Judenhofer MS; Röcken M; Machulla HJ; Pichler BJ
Radiat Oncol; 2011 Nov; 6():165. PubMed ID: 22118419
[TBL] [Abstract][Full Text] [Related]
11. β -[
Kumar P; Roselt P; Reischl G; Cullinane C; Beiki D; Ehrlichmann W; Binns D; Naimi E; Yang J; Hicks R; Machulla HJ; Wiebe LI
Curr Radiopharm; 2017; 10(2):93-101. PubMed ID: 28294075
[TBL] [Abstract][Full Text] [Related]
12. [
Schweifer A; Maier F; Ehrlichmann W; Lamparter D; Kneilling M; Pichler BJ; Hammerschmidt F; Reischl G
Nucl Med Biol; 2016 Dec; 43(12):759-769. PubMed ID: 27693670
[TBL] [Abstract][Full Text] [Related]
13. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors.
Sorger D; Patt M; Kumar P; Wiebe LI; Barthel H; Seese A; Dannenberg C; Tannapfel A; Kluge R; Sabri O
Nucl Med Biol; 2003 Apr; 30(3):317-26. PubMed ID: 12745023
[TBL] [Abstract][Full Text] [Related]
14. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts.
Troost EG; Laverman P; Philippens ME; Lok J; van der Kogel AJ; Oyen WJ; Boerman OC; Kaanders JH; Bussink J
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1803-11. PubMed ID: 18421457
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Analysis of Dynamic
Schwartz J; Grkovski M; Rimner A; Schöder H; Zanzonico PB; Carlin SD; Staton KD; Humm JL; Nehmeh SA
J Nucl Med; 2017 Jun; 58(6):911-919. PubMed ID: 28232611
[TBL] [Abstract][Full Text] [Related]
17. Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia--a simulation study.
Wack LJ; Mönnich D; van Elmpt W; Zegers CM; Troost EG; Zips D; Thorwarth D
Acta Oncol; 2015; 54(9):1370-7. PubMed ID: 26203928
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Bioevaluation of Novel [
Yang X; Wang F; Zhu H; Yang Z; Chu T
Mol Pharm; 2019 May; 16(5):2118-2128. PubMed ID: 30964298
[TBL] [Abstract][Full Text] [Related]
19. Kinetic Evaluation of the Hypoxia Radiotracers [
Choen S; Kent MS; Chaudhari AJ; Cherry SR; Krtolica A; Zwingenberger AL
Nucl Med Mol Imaging; 2023 Feb; 57(1):16-25. PubMed ID: 36643946
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers.
Carlin S; Zhang H; Reese M; Ramos NN; Chen Q; Ricketts SA
J Nucl Med; 2014 Mar; 55(3):515-21. PubMed ID: 24491409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
